Pentapeptide-18

What is Pentapeptide-18?

Pentapeptide-18 is the INCI name for the synthetic pentapeptide Tyr-D-Ala-Gly-Phe-Leu; Leuphasyl is Lipotec's (now Lubrizol's) trade name for a dilute solution of it sold as a cosmeceutical anti-wrinkle ingredient. Chemically, the sequence is [D-Ala2]-leucine-enkephalin, an enkephalin analog long used as a research tool in opioid pharmacology. Its design is based on the natural enkephalin opioid pentapeptides — leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) and methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) — with a D-alanine substitution at position 2 that improves enzymatic stability. The proposed cosmetic mechanism is that, like natural enkephalins, it binds to opioid receptors on presynaptic nerve terminals, triggering a G-protein cascade that closes calcium channels and opens potassium channels. This would reduce calcium influx, preventing synaptic vesicle fusion and decreasing acetylcholine release across the neuromuscular junction. The result is reduced muscle contraction intensity and softer expression wrinkles — particularly forehead lines and crow's feet. Unlike Argireline (which blocks SNARE complex assembly) or Syn-Ake (which blocks the postsynaptic receptor), Pentapeptide-18 works upstream by mimicking the body's own inhibitory signaling.

What Pentapeptide-18 Is Investigated For

Pentapeptide-18 (Leuphasyl) is a topical cosmeceutical enkephalin mimetic used to reduce expression wrinkles — forehead lines, crow's feet, glabellar creases — by modulating presynaptic acetylcholine release at the neuromuscular junction, and is commonly stacked with Argireline for a synergistic anti-wrinkle effect. The human evidence rests on two small studies, one run by the manufacturer and one independent study without a vehicle control. In Lipotec's 28-day comparison (as summarized in Gorouhi and Maibach's 2009 review), creams with 5% Leuphasyl solution, 5% Argireline solution, or both reduced wrinkles by 11.64%, 16.26%, and 24.62% on average. In an independent 20-volunteer study from Timișoara (Dragomirescu et al. 2014), a 2% Leuphasyl emulsion applied daily for 60 days shortened wrinkle length on 2D imaging by 34.7% between the eyebrows and 28.4% around the eyes; 0.5% and 1% showed no important improvement, there was no vehicle control, and the authors noted their method could not measure wrinkle depth. Note that these percentages refer to the Leuphasyl trade solution in the cream, not pure peptide. The enkephalin/δ-opioid-receptor presynaptic inhibition mechanism is pharmacologically sound, though whether meaningful receptor engagement occurs through intact skin at cosmeceutical concentrations is the central unresolved question. Most published efficacy data comes from manufacturer-sponsored work with thin independent replication, and effect sizes are far smaller and slower than botulinum toxin injection. Genuine cosmetic active with documented signal, not 'topical Botox.'

History & Discovery

Pentapeptide-18 (Leuphasyl) was developed by Lipotec S.A. in Barcelona — the same Spanish peptide company behind Argireline (acetyl hexapeptide-8) and SNAP-8 (acetyl octapeptide-3) — and trademarked in the mid-2000s as a cosmeceutical anti-wrinkle ingredient. The design rationale stepped sideways from the SNARE-targeting approach Lipotec had used for Argireline: instead of competing with SNAP-25 to inhibit vesicle fusion, Leuphasyl was designed to mimic the body's own enkephalin opioid pentapeptides — leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) and methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) — which engage opioid receptors on presynaptic motor nerve terminals to dampen neurotransmitter release. Lipotec's design substituted D-alanine for glycine at position 2 (Tyr-D-Ala-Gly-Phe-Leu) to confer resistance to enzymatic degradation by aminopeptidases — a stability strategy borrowed from the broader opioid peptide pharmacology literature. The marketing positioning was distinct from Argireline: while Argireline blocked the SNARE complex downstream, Leuphasyl was pitched as an upstream modulator that worked via the same inhibitory pathway the body itself uses to dial down nerve signaling. The two peptides were positioned as synergistic — Lipotec's 28-day comparison reported 11.64% average wrinkle reduction for Leuphasyl, 16.26% for Argireline, and 24.62% for the two together, figures later carried into the peer-reviewed literature by Gorouhi and Maibach's 2009 review of topical peptides. Lipotec was acquired by Lubrizol in 2012, and Leuphasyl continues to be marketed under that umbrella; Pentapeptide-18 is the INCI name that appears on ingredient lists. The main independent human study came from the Faculty of Pharmacy in Timișoara, Romania (Dragomirescu et al., Cosmetics 2014). Its 20 volunteers applied emulsions with 0.5%, 1%, or 2% Leuphasyl once daily for 60 days, and only the 2% version produced important improvement. The authors argued that products should be applied over the muscle that creates the line rather than along the wrinkle itself. The paper also refers to Leuphasyl as 'pentapeptid-3' — an error, since Pentapeptide-3 is the INCI name of Vialox. Independent peer-reviewed efficacy data on the peptide remains thin.

How It Works

Before your facial muscles contract, a nerve signal triggers the release of acetylcholine — the chemical messenger that tells the muscle to move. Your body naturally has enkephalins, small peptides that can dial down this nerve signaling. Pentapeptide-18 mimics these enkephalins: it binds to receptors on the nerve ending and tells the cell to reduce its activity. With less acetylcholine released, your facial muscles contract less intensely, and the expression wrinkles they create (like forehead lines and crow's feet) gradually soften.

Pentapeptide-18 (H-Tyr-D-Ala-Gly-Phe-Leu-OH, MW 569.6 g/mol) is [D-Ala2]-leucine-enkephalin: a synthetic analog of leucine-enkephalin with a D-alanine substitution at position 2 that confers resistance to aminopeptidase degradation. In opioid pharmacology this analog is an agonist at δ- (and μ-) opioid receptors; the cosmetic claim is that it acts at opioid receptors on presynaptic motor nerve terminals in facial muscle. Upon binding, the receptor couples to inhibitory Gi/Go proteins, activating a signaling cascade that closes voltage-gated calcium channels (VGCCs) and opens inwardly rectifying potassium channels (GIRKs). Reduced Ca2+ influx prevents synaptic vesicle docking and fusion with the presynaptic membrane, thereby inhibiting acetylcholine exocytosis across the neuromuscular junction. This presynaptic mechanism is complementary to Argireline's SNARE complex inhibition (also presynaptic but downstream) and Syn-Ake's postsynaptic nicotinic receptor antagonism, enabling multi-target combination strategies. Direct evidence that topical Pentapeptide-18 reduces acetylcholine release at human facial neuromuscular junctions has not been published; the cascade is inferred from enkephalin pharmacology and manufacturer in vitro work. Two 2026 papers explored other possible actions, both largely computational. One (PMID: 41722287) characterized the peptide's structure with DFT calculations and FTIR/Raman spectroscopy and docked it against TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB targets — modeling, not biological evidence of activity. The other (PMID: 42116636) docked Leuphasyl and Vialox against collagen-degrading MMP-1, MMP-8, and MMP-13 and against SIRT-1, finding Leuphasyl bound MMP-13 most strongly, and showed neither peptide was toxic to HaCaT keratinocytes at up to 1 mg/mL. Separately, Park et al. (2020, PMID: 31937863) found that adding a D-tyrosine to the end of Pentapeptide-18 — creating a new molecule — gave it the ability to reduce melanin content and tyrosinase activity in MNT-1 melanoma cells and primary melanocytes, and to reduce melanin synthesis in a 3D human skin model; unmodified Pentapeptide-18 is not a skin-brightening ingredient.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Pentapeptide-18:

• 01Independent, non-industry-funded, vehicle-controlled human trials on Pentapeptide-18 specifically — most efficacy claims trace back to Lipotec/Lubrizol data, and the one independent study (Dragomirescu et al. 2014) had 20 volunteers, no vehicle control, and no statistical testing.
• 02Wrinkle-depth measurement — the independent study measured wrinkle length in 2D and stated it could not assess depth; no published study has used 3D profilometry or replica analysis on Pentapeptide-18 alone.
• 03Direct head-to-head comparisons with botulinum toxin (the implicit comparator), Argireline, Syn-Ake, and Vialox at matched concentrations and durations.
• 04Real-world skin-penetration and target-site quantification — whether the pentapeptide actually reaches presynaptic δ-opioid receptors at facial neuromuscular junctions in clinically meaningful concentrations from topical application is the central unresolved question.
• 05Long-term human data — most published work spans 28- to 60-day windows; multi-month and multi-year continuous use has not been studied as a distinct safety or efficacy question.
• 06Whether the manufacturer's claimed Argireline + Leuphasyl synergy (24.62% combined vs. 11.64% Leuphasyl alone and 16.26% Argireline alone) holds up in independent trials at multiple concentrations and durations.
• 07Translation of the D-tyrosine-extended Pentapeptide-18 anti-melanogenic findings (Park et al. 2020, cells and a 3D skin model) into clinical pigmentation endpoints — the derivative is a different molecule, and no human data exist.
• 08Whether the 2026 computational pathway analyses (TGF-β, TNF-α, MAPK, PI3K/AKT, NF-κB) translate into measurable in vivo anti-aging effects beyond neuromuscular modulation.

Forms & Administration

Pentapeptide-18 is used topically in cosmeceutical formulations — serums, creams, and eye treatments. Published studies used 2% (Dragomirescu) to 5% (Lipotec) of the Leuphasyl trade solution in the finished product; because the solution is dilute, the actual peptide content is a small fraction of a percent. Dragomirescu et al. recommend applying it over the muscle that forms the line (between the eyebrows, around the eyes) rather than only along the crease. Most effective when combined with Argireline (acetyl hexapeptide-8) for synergistic expression line reduction, and sometimes paired with Matrixyl (collagen stimulation) or Syn-Ake (postsynaptic receptor blocking) for multi-target anti-aging. Applied to clean skin once or twice daily (the independent study used once daily). No prescription required for cosmeceutical products. Advanced delivery systems such as solid lipid nanoparticles have been explored to improve skin penetration and stability.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Pentapeptide-18 is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language. Despite mimicking enkephalin structure, topical use at cosmetic concentrations does not produce systemic opioid effects — this is not an opioid analgesic and has no abuse potential at topical cosmetic exposure. Do not inject cosmetic peptide products.

Timeline of Effects

Common Questions

Who Pentapeptide-18 Is NOT For

Drug & Supplement Interactions

Documented pharmacological drug interactions for topical Pentapeptide-18 are minimal. Systemic absorption from typical topical use is low enough that meaningful interaction with oral or injected medications is not expected. The opioid-mimetic structure does not translate into systemic opioid effects at topical cosmetic exposure, and there is no documented interaction with prescription opioid analgesics, opioid antagonists (naloxone, naltrexone), or buprenorphine at the level of topical use. The practical interaction space is topical layering with other actives. Pentapeptide-18 is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Argireline is the most common stacking pattern and is mechanistically complementary (presynaptic upstream modulation + presynaptic downstream SNARE inhibition). Pairing with postsynaptic blockers (Syn-Ake, Vialox) hits a third point in the neuromuscular cascade and is also mechanistically distinct. Layering with matrikine peptides (Matrixyl, Syn-Coll) combines independent mechanisms. High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Pentapeptide-18 can reduce peptide activity at the surface and increase irritation. Patients receiving botulinum toxin injection generally do not need to stop Pentapeptide-18 beforehand.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions